Share Price and Basic Stock Data
Last Updated: August 1, 2025, 2:01 pm
| PEG Ratio | 0.98 |
|---|
Quick Insight
Unichem Laboratories Ltd, with a current share price of ₹641 and a market capitalization of ₹4,513 Cr., exhibits a P/E ratio of 33.0, indicating potential overvaluation. The company's ROE stands at 5.59%, while ROCE is at 6.24%, reflecting moderate returns on equity and capital employed. With OPM at 14%, the firm faces profitability challenges amidst industry competition. Notably, Unichem's reserves amount to ₹2,437 Cr, with borrowings at ₹460 Cr, suggesting a stable financial position. However, the high CCC of 353 days raises concerns about liquidity management. Investors may find the P/BV ratio of 1.99x attractive, although thorough due diligence is warranted given the moderate ICR of 14.27x.
Competitors of Unichem Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 140 Cr. | 99.1 | 247/84.3 | 27.1 | 41.7 | 0.00 % | 12.9 % | 9.75 % | 10.0 |
| MPS Pharmaa Ltd | 4.72 Cr. | 2.47 | 4.33/2.47 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.6 Cr. | 49.4 | 94.9/45.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 31.7 Cr. | 21.6 | 29.1/13.1 | 31.1 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,945.06 Cr | 1,196.56 | 53.47 | 193.55 | 0.32% | 16.61% | 15.24% | 6.18 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 370 | 310 | 329 | 302 | 402 | 423 | 416 | 466 | 432 | 446 | 507 | 533 | 587 |
| Expenses | 302 | 311 | 347 | 345 | 386 | 395 | 407 | 435 | 406 | 403 | 452 | 448 | 503 |
| Operating Profit | 68 | -1 | -18 | -43 | 16 | 28 | 9 | 31 | 25 | 44 | 55 | 86 | 84 |
| OPM % | 18% | -0% | -6% | -14% | 4% | 7% | 2% | 7% | 6% | 10% | 11% | 16% | 14% |
| Other Income | 14 | 8 | 4 | 16 | -28 | 9 | 6 | 79 | -119 | 4 | 9 | 14 | 9 |
| Interest | 2 | 3 | 5 | 4 | 6 | 6 | 7 | 6 | 5 | 4 | 5 | 7 | 5 |
| Depreciation | 23 | 25 | 28 | 31 | 30 | 29 | 29 | 32 | 27 | 28 | 32 | 31 | 30 |
| Profit before tax | 58 | -21 | -47 | -61 | -47 | 2 | -22 | 73 | -126 | 15 | 27 | 62 | 58 |
| Tax % | -23% | 13% | 50% | 4% | -6% | 132% | 12% | -0% | 3% | 38% | 9% | 6% | 8% |
| Net Profit | 71 | -23 | -71 | -64 | -44 | -1 | -24 | 73 | -129 | 9 | 25 | 58 | 53 |
| EPS in Rs | 10.15 | -3.32 | -10.04 | -9.08 | -6.29 | -0.10 | -3.48 | 10.40 | -18.37 | 1.32 | 3.50 | 8.22 | 7.52 |
Last Updated: May 31, 2025, 7:26 am
Below is a detailed analysis of the quarterly data for Unichem Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 587.00 Cr.. The value appears strong and on an upward trend. It has increased from 533.00 Cr. (Dec 2024) to 587.00 Cr., marking an increase of 54.00 Cr..
- For Expenses, as of Mar 2025, the value is 503.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 448.00 Cr. (Dec 2024) to 503.00 Cr., marking an increase of 55.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 84.00 Cr.. The value appears to be declining and may need further review. It has decreased from 86.00 Cr. (Dec 2024) to 84.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Mar 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Dec 2024) to 14.00%, marking a decrease of 2.00%.
- For Other Income, as of Mar 2025, the value is 9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 9.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Mar 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.00 Cr. (Dec 2024) to 5.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Mar 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 31.00 Cr. (Dec 2024) to 30.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 62.00 Cr. (Dec 2024) to 58.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Mar 2025, the value is 8.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Dec 2024) to 8.00%, marking an increase of 2.00%.
- For Net Profit, as of Mar 2025, the value is 53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Dec 2024) to 53.00 Cr., marking a decrease of 5.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 7.52. The value appears to be declining and may need further review. It has decreased from 8.22 (Dec 2024) to 7.52, marking a decrease of 0.70.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 2:48 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,133 | 1,202 | 1,333 | 698 | 815 | 1,180 | 1,104 | 1,235 | 1,270 | 1,343 | 1,785 | 2,111 |
| Expenses | 956 | 1,100 | 1,169 | 738 | 942 | 1,254 | 1,153 | 1,144 | 1,198 | 1,389 | 1,698 | 1,846 |
| Operating Profit | 178 | 101 | 164 | -41 | -128 | -74 | -49 | 91 | 72 | -46 | 87 | 265 |
| OPM % | 16% | 8% | 12% | -6% | -16% | -6% | -4% | 7% | 6% | -3% | 5% | 13% |
| Other Income | 83 | 20 | 15 | 184 | 2,735 | 91 | 91 | 50 | 47 | -0 | -26 | 35 |
| Interest | 3 | 3 | 3 | 3 | 8 | 8 | 8 | 5 | 6 | 17 | 23 | 21 |
| Depreciation | 46 | 41 | 39 | 44 | 51 | 67 | 82 | 84 | 91 | 113 | 123 | 125 |
| Profit before tax | 212 | 77 | 137 | 97 | 2,548 | -58 | -48 | 51 | 22 | -176 | -85 | 155 |
| Tax % | 20% | 3% | 21% | -12% | 0% | -59% | 25% | 33% | -50% | 15% | 10% | 11% |
| Net Profit | 169 | 75 | 108 | 109 | 2,545 | -24 | -60 | 34 | 33 | -202 | -94 | 138 |
| EPS in Rs | 18.68 | 8.31 | 11.90 | 11.96 | 361.82 | -3.38 | -8.55 | 4.87 | 4.70 | -28.72 | -13.32 | 19.53 |
| Dividend Payout % | 43% | 24% | 17% | 25% | 1% | -118% | -47% | 82% | 85% | -14% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -55.62% | 44.00% | 0.93% | 2234.86% | -100.94% | -150.00% | 156.67% | -2.94% | -712.12% | 53.47% | 246.81% |
| Change in YoY Net Profit Growth (%) | 0.00% | 99.62% | -43.07% | 2233.94% | -2335.81% | -49.06% | 306.67% | -159.61% | -709.18% | 765.59% | 193.34% |
Unichem Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 29% |
| 3 Years: | 63% |
| TTM: | 414% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 17% |
| 3 Years: | 28% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 0% |
| 3 Years: | -1% |
| Last Year: | 6% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 2:09 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 798 | 849 | 936 | 1,045 | 2,666 | 2,606 | 2,517 | 2,543 | 2,604 | 2,421 | 2,424 | 2,437 |
| Borrowings | 26 | 22 | 36 | 98 | 151 | 200 | 206 | 119 | 349 | 314 | 248 | 460 |
| Other Liabilities | 302 | 264 | 283 | 359 | 359 | 323 | 407 | 436 | 351 | 444 | 589 | 659 |
| Total Liabilities | 1,145 | 1,153 | 1,274 | 1,521 | 3,190 | 3,142 | 3,145 | 3,112 | 3,319 | 3,193 | 3,275 | 3,569 |
| Fixed Assets | 419 | 416 | 403 | 491 | 578 | 810 | 870 | 884 | 990 | 1,257 | 1,252 | 1,300 |
| CWIP | 91 | 123 | 237 | 250 | 238 | 92 | 330 | 568 | 494 | 147 | 123 | 31 |
| Investments | 11 | 41 | 14 | 14 | 901 | 926 | 550 | 392 | 264 | 2 | 1 | 0 |
| Other Assets | 623 | 574 | 620 | 766 | 1,473 | 1,313 | 1,395 | 1,269 | 1,571 | 1,787 | 1,898 | 2,239 |
| Total Assets | 1,145 | 1,153 | 1,274 | 1,521 | 3,190 | 3,142 | 3,145 | 3,112 | 3,319 | 3,193 | 3,275 | 3,569 |
Below is a detailed analysis of the balance sheet data for Unichem Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,437.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,424.00 Cr. (Mar 2024) to 2,437.00 Cr., marking an increase of 13.00 Cr..
- For Borrowings, as of Mar 2025, the value is 460.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 248.00 Cr. (Mar 2024) to 460.00 Cr., marking an increase of 212.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 659.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 589.00 Cr. (Mar 2024) to 659.00 Cr., marking an increase of 70.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,569.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,275.00 Cr. (Mar 2024) to 3,569.00 Cr., marking an increase of 294.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,300.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,252.00 Cr. (Mar 2024) to 1,300.00 Cr., marking an increase of 48.00 Cr..
- For CWIP, as of Mar 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Mar 2024) to 31.00 Cr., marking a decrease of 92.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,239.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,898.00 Cr. (Mar 2024) to 2,239.00 Cr., marking an increase of 341.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,569.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,275.00 Cr. (Mar 2024) to 3,569.00 Cr., marking an increase of 294.00 Cr..
Notably, the Reserves (2,437.00 Cr.) exceed the Borrowings (460.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 152.00 | 79.00 | 128.00 | -139.00 | -279.00 | -274.00 | -255.00 | -28.00 | -277.00 | -360.00 | -161.00 | -195.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70 | 63 | 58 | 60 | 165 | 124 | 135 | 129 | 74 | 142 | 160 | 131 |
| Inventory Days | 132 | 192 | 171 | 184 | 397 | 278 | 278 | 374 | 518 | 527 | 414 | 387 |
| Days Payable | 145 | 142 | 114 | 131 | 297 | 230 | 182 | 236 | 202 | 161 | 193 | 164 |
| Cash Conversion Cycle | 57 | 113 | 116 | 113 | 265 | 172 | 231 | 267 | 390 | 508 | 382 | 353 |
| Working Capital Days | 59 | 95 | 89 | 94 | 225 | 200 | 227 | 217 | 194 | 277 | 272 | 217 |
| ROCE % | 20% | 19% | 9% | 15% | 9% | 128% | -2% | -2% | 2% | 1% | -5% | 0% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund - Regular Plan | 5,473,134 | 0.9 | 256.12 | 5,473,134 | 2025-04-22 17:25:16 | 0% |
| DSP Healthcare Fund | 735,591 | 1.58 | 34.42 | 735,591 | 2025-04-22 17:25:16 | 0% |
| Franklin India Opportunities Fund | 313,225 | 0.59 | 14.66 | 313,225 | 2025-04-22 17:25:17 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 366 | 0.17 | 0.02 | 366 | 2025-04-22 17:25:17 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| Diluted EPS (Rs.) | 19.47 | -10.01 | -28.72 | 4.70 | 4.88 |
| Cash EPS (Rs.) | 37.23 | 6.07 | -7.13 | 17.80 | 16.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 348.10 | 335.54 | 345.89 | 371.90 | 363.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 348.10 | 335.54 | 345.89 | 371.90 | 363.16 |
| Revenue From Operations / Share (Rs.) | 299.85 | 242.15 | 190.75 | 180.36 | 175.43 |
| PBDIT / Share (Rs.) | 42.64 | 18.73 | -0.99 | 17.09 | 20.07 |
| PBIT / Share (Rs.) | 24.95 | 2.64 | -17.11 | 4.14 | 8.09 |
| PBT / Share (Rs.) | 21.96 | -8.76 | -19.57 | 3.27 | 7.36 |
| Net Profit / Share (Rs.) | 19.53 | -10.01 | -23.25 | 4.85 | 4.92 |
| NP After MI And SOA / Share (Rs.) | 19.53 | -10.01 | -28.72 | 4.70 | 4.88 |
| PBDIT Margin (%) | 14.22 | 7.73 | -0.52 | 9.47 | 11.43 |
| PBIT Margin (%) | 8.31 | 1.09 | -8.97 | 2.29 | 4.61 |
| PBT Margin (%) | 7.32 | -3.61 | -10.26 | 1.81 | 4.19 |
| Net Profit Margin (%) | 6.51 | -4.13 | -12.18 | 2.68 | 2.80 |
| NP After MI And SOA Margin (%) | 6.51 | -4.13 | -15.05 | 2.60 | 2.77 |
| Return on Networth / Equity (%) | 5.61 | -2.98 | -8.30 | 1.26 | 1.34 |
| Return on Capital Employeed (%) | 6.81 | 0.75 | -4.71 | 1.05 | 2.17 |
| Return On Assets (%) | 3.85 | -2.22 | -6.33 | 0.99 | 1.09 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.02 | 0.03 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.09 | 0.12 | 0.12 | 0.03 |
| Asset Turnover Ratio (%) | 0.62 | 0.53 | 0.41 | 0.30 | 0.35 |
| Current Ratio (X) | 2.05 | 2.40 | 2.49 | 2.99 | 2.72 |
| Quick Ratio (X) | 1.06 | 1.40 | 1.51 | 1.90 | 1.66 |
| Inventory Turnover Ratio (X) | 1.05 | 1.12 | 0.86 | 0.87 | 1.15 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 85.18 | 82.04 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 22.66 | 23.72 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 14.82 | 17.96 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 77.34 | 76.28 |
| Interest Coverage Ratio (X) | 14.27 | 5.82 | -0.40 | 19.70 | 27.60 |
| Interest Coverage Ratio (Post Tax) (X) | 7.54 | 0.43 | -8.45 | 6.59 | 7.77 |
| Enterprise Value (Cr.) | 5189.65 | 3504.16 | 2147.12 | 2049.28 | 2195.83 |
| EV / Net Operating Revenue (X) | 2.46 | 2.06 | 1.60 | 1.61 | 1.78 |
| EV / EBITDA (X) | 17.29 | 26.58 | -304.97 | 17.03 | 15.54 |
| MarketCap / Net Operating Revenue (X) | 2.31 | 2.02 | 1.52 | 1.44 | 1.76 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 14.81 | 17.95 |
| Price / BV (X) | 1.99 | 1.46 | 0.83 | 0.70 | 0.85 |
| Price / Net Operating Revenue (X) | 2.31 | 2.02 | 1.52 | 1.44 | 1.76 |
| EarningsYield | 0.02 | -0.02 | -0.09 | 0.01 | 0.01 |
After reviewing the key financial ratios for Unichem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.47. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.47, marking an increase of 29.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 37.23. This value is within the healthy range. It has increased from 6.07 (Mar 24) to 37.23, marking an increase of 31.16.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 348.10. It has increased from 335.54 (Mar 24) to 348.10, marking an increase of 12.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 299.85. It has increased from 242.15 (Mar 24) to 299.85, marking an increase of 57.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 42.64. This value is within the healthy range. It has increased from 18.73 (Mar 24) to 42.64, marking an increase of 23.91.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.95. This value is within the healthy range. It has increased from 2.64 (Mar 24) to 24.95, marking an increase of 22.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.96. This value is within the healthy range. It has increased from -8.76 (Mar 24) to 21.96, marking an increase of 30.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.53. This value is within the healthy range. It has increased from -10.01 (Mar 24) to 19.53, marking an increase of 29.54.
- For PBDIT Margin (%), as of Mar 25, the value is 14.22. This value is within the healthy range. It has increased from 7.73 (Mar 24) to 14.22, marking an increase of 6.49.
- For PBIT Margin (%), as of Mar 25, the value is 8.31. This value is below the healthy minimum of 10. It has increased from 1.09 (Mar 24) to 8.31, marking an increase of 7.22.
- For PBT Margin (%), as of Mar 25, the value is 7.32. This value is below the healthy minimum of 10. It has increased from -3.61 (Mar 24) to 7.32, marking an increase of 10.93.
- For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from -4.13 (Mar 24) to 6.51, marking an increase of 10.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.61. This value is below the healthy minimum of 15. It has increased from -2.98 (Mar 24) to 5.61, marking an increase of 8.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.81. This value is below the healthy minimum of 10. It has increased from 0.75 (Mar 24) to 6.81, marking an increase of 6.06.
- For Return On Assets (%), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 5. It has increased from -2.22 (Mar 24) to 3.85, marking an increase of 6.07.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.17, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.62. It has increased from 0.53 (Mar 24) to 0.62, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 2.05. This value is within the healthy range. It has decreased from 2.40 (Mar 24) to 2.05, marking a decrease of 0.35.
- For Quick Ratio (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.06, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 4. It has decreased from 1.12 (Mar 24) to 1.05, marking a decrease of 0.07.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14.27. This value is within the healthy range. It has increased from 5.82 (Mar 24) to 14.27, marking an increase of 8.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.54. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 7.54, marking an increase of 7.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,189.65. It has increased from 3,504.16 (Mar 24) to 5,189.65, marking an increase of 1,685.49.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 2.46, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.29. This value exceeds the healthy maximum of 15. It has decreased from 26.58 (Mar 24) to 17.29, marking a decrease of 9.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has increased from 1.46 (Mar 24) to 1.99, marking an increase of 0.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has increased from 2.02 (Mar 24) to 2.31, marking an increase of 0.29.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.02, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Unichem Laboratories Ltd:
- Net Profit Margin: 6.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.81% (Industry Average ROCE: 16.61%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.61% (Industry Average ROE: 15.24%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.54
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31.4 (Industry average Stock P/E: 53.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.51%
About the Company - Qualitative Analysis
Unichem Laboratories Ltd. is a Public Limited Listed company incorporated on 22/08/1962 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1962PLC012451 and registration number is 012451. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 1735.70 Cr. and Equity Capital is Rs. 14.08 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 47, Kandivli Industrial Estate, Mumbai Maharashtra 400067 | shares@unichemlabs.com http://www.unichemlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prakash A Mody | Chairman, Non Ind & Non Exe Director |
| Mr. Pabitrakumar Bhattacharyya | Managing Director |
| Mr. Pranay Godha | Non Exe.Non Ind.Director |
| Ms. Priti Puri | Independent Director |
| Mr. Anand Kusre | Independent Director |
| Mr. Arun Todarwal | Independent Director |
FAQ
What is the intrinsic value of Unichem Laboratories Ltd?
Unichem Laboratories Ltd's intrinsic value (as of 02 August 2025) is 498.44 18.15% lower the current market price of 609.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,290 Cr. market cap, FY2025-2026 high/low of 950/528, reserves of 2,437 Cr, and liabilities of 3,569 Cr.
What is the Market Cap of Unichem Laboratories Ltd?
The Market Cap of Unichem Laboratories Ltd is 4,290 Cr..
What is the current Stock Price of Unichem Laboratories Ltd as on 02 August 2025?
The current stock price of Unichem Laboratories Ltd as on 02 August 2025 is 609.
What is the High / Low of Unichem Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Unichem Laboratories Ltd stocks is ₹950/528.
What is the Stock P/E of Unichem Laboratories Ltd?
The Stock P/E of Unichem Laboratories Ltd is 31.4.
What is the Book Value of Unichem Laboratories Ltd?
The Book Value of Unichem Laboratories Ltd is 348.
What is the Dividend Yield of Unichem Laboratories Ltd?
The Dividend Yield of Unichem Laboratories Ltd is 0.00 %.
What is the ROCE of Unichem Laboratories Ltd?
The ROCE of Unichem Laboratories Ltd is 6.24 %.
What is the ROE of Unichem Laboratories Ltd?
The ROE of Unichem Laboratories Ltd is 5.59 %.
What is the Face Value of Unichem Laboratories Ltd?
The Face Value of Unichem Laboratories Ltd is 2.00.